Wall Street analysts forecast that BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) will announce earnings of ($0.31) per share for the current quarter, Zacks Investment Research reports. Four analysts have made estimates for BioCryst Pharmaceuticals’ earnings, with the lowest EPS estimate coming in at ($0.34) and the highest estimate coming in at ($0.25). BioCryst Pharmaceuticals reported earnings of ($0.19) per share in the same quarter last year, which would suggest a negative year over year growth rate of 63.2%. The business is expected to issue its next earnings results on Tuesday, August 6th.
According to Zacks, analysts expect that BioCryst Pharmaceuticals will report full-year earnings of ($1.21) per share for the current year, with EPS estimates ranging from ($1.27) to ($1.14). For the next financial year, analysts anticipate that the firm will post earnings of ($0.99) per share, with EPS estimates ranging from ($1.35) to ($0.69). Zacks Investment Research’s EPS calculations are an average based on a survey of analysts that follow BioCryst Pharmaceuticals.
BioCryst Pharmaceuticals (NASDAQ:BCRX) last posted its quarterly earnings data on Wednesday, May 8th. The biotechnology company reported ($0.28) earnings per share for the quarter, meeting the Zacks’ consensus estimate of ($0.28). BioCryst Pharmaceuticals had a negative net margin of 472.12% and a negative return on equity of 223.34%. The business had revenue of $5.89 million for the quarter, compared to analysts’ expectations of $2.92 million.
BCRX has been the subject of several research reports. Jefferies Financial Group dropped their target price on BioCryst Pharmaceuticals from $13.00 to $8.00 and set a “buy” rating for the company in a research report on Wednesday, May 22nd. HC Wainwright initiated coverage on in a research note on Wednesday, May 22nd. They set a “buy” rating for the company. Piper Jaffray Companies set a $15.00 target price on BioCryst Pharmaceuticals and gave the stock a “buy” rating in a research note on Monday, April 22nd. Barclays set a €16.80 ($19.53) target price on Deutsche Telekom and gave the stock a “neutral” rating in a research note on Tuesday, April 2nd. Finally, Royal Bank of Canada restated a “buy” rating on shares of PrairieSky Royalty in a research note on Friday, May 24th. Six research analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. BioCryst Pharmaceuticals presently has an average rating of “Hold” and a consensus price target of $9.56.
BioCryst Pharmaceuticals stock traded up $0.02 during mid-day trading on Friday, hitting $3.60. The company had a trading volume of 760,900 shares, compared to its average volume of 1,508,226. The company has a debt-to-equity ratio of 2.38, a current ratio of 1.77 and a quick ratio of 1.76. BioCryst Pharmaceuticals has a 12-month low of $2.80 and a 12-month high of $9.95. The firm’s fifty day moving average is $3.54. The stock has a market cap of $396.01 million, a P/E ratio of -3.67 and a beta of 2.05.
In other BioCryst Pharmaceuticals news, CFO Thomas R. Staab II sold 7,750 shares of the business’s stock in a transaction that occurred on Thursday, May 2nd. The stock was sold at an average price of $7.30, for a total value of $56,575.00. Following the completion of the sale, the chief financial officer now owns 140,426 shares in the company, valued at $1,025,109.80. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, insider Thomas R. Staab II sold 19,500 shares of the business’s stock in a transaction that occurred on Monday, May 13th. The shares were sold at an average price of $7.70, for a total value of $150,150.00. Following the completion of the sale, the insider now owns 142,426 shares of the company’s stock, valued at approximately $1,096,680.20. The disclosure for this sale can be found here. In the last quarter, insiders sold 67,500 shares of company stock valued at $517,223. 5.20% of the stock is owned by company insiders.
Several large investors have recently added to or reduced their stakes in BCRX. Paloma Partners Management Co acquired a new position in shares of BioCryst Pharmaceuticals in the fourth quarter valued at approximately $84,000. Amalgamated Bank acquired a new position in shares of BioCryst Pharmaceuticals in the fourth quarter valued at approximately $122,000. Summit Securities Group LLC acquired a new position in shares of BioCryst Pharmaceuticals in the first quarter valued at approximately $132,000. Legal & General Group Plc increased its holdings in shares of BioCryst Pharmaceuticals by 14.5% in the fourth quarter. Legal & General Group Plc now owns 19,315 shares of the biotechnology company’s stock valued at $156,000 after purchasing an additional 2,453 shares during the period. Finally, SG Americas Securities LLC acquired a new position in shares of BioCryst Pharmaceuticals in the first quarter valued at approximately $169,000. 91.98% of the stock is currently owned by institutional investors and hedge funds.
About BioCryst Pharmaceuticals
BioCryst Pharmaceuticals, Inc, a biotechnology company, discovers oral and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor, for the treatment of acute uncomplicated influenza under the RAPIVAB, ALPIVAB, RAPIACTA, and PERAMIFLU names; and Mundesine, an oral purine nucleoside phosphorylase inhibitor for peripheral T-cell lymphoma.
Further Reading: What are different types of coverage ratios?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for BioCryst Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioCryst Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.